



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/735 638		De La Charniere	

EXAMINER	
Kishore	
ART UNIT	PAPER NUMBER
1615	10

DATE MAILED:

EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

(1) G.S. KISHORE (3) _____

(2) Kathy Baumeister (4) _____

Date of interview 5-29-02

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☒ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No. If yes, brief description: _____

Agreement ☐ was reached with respect to some or all of the claims in question. ☒ was not reached.

Claims discussed: Proposed independent claims 25, 55 & 85-

Identification of prior art discussed: Prior art on record

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: Ms Baumeister discussed

the proposed claims which recite the symptoms and causative factors. The examiner will carefully review the claims and determine the allowability. Since the application is under final, the amendments may or may not be entered

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

Unless the paragraphs below have been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

☐ Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action.

G.S. Kishore
G.S. Kishore, PhD
Primary Examiner,
Group 1600

Examiner's Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Olivier DE LACHARRIERE et al.)	Group Art Unit: 1615
)	
Application No.: 09/735,638)	Examiner: G. Kishore
)	
Filed: December 14, 2000)	
)	
For: USE OF A SUBSTANCE P)	
ANTAGONIST IN A COSMETIC)	
COMPOSITION, AND THE)	
COMPOSITION THUS OBTAINED)	
)	

SUMMARY OF PROPOSAL II FOR INTERVIEW

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Amend the independent claims, Claims 25, 55 and 85, as set forth below.

Cancel Claims 27, 57 and 87.

This will leave Claims 25, 26, 28-51, 53-56, 58-81, 83-86, 88-111 and 113-114 in the application. (Claims 52, 82 and 112 were cancelled in the amendment dated November 5, 2001.)

25. (Twice Amended) A cosmetic or dermatological method for treating sensitive skin of an individual in need of such treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by exhibiting at least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema, in reaction to at least one

Sensitive skin
allergic rx

factor selected from the group consisting of food, wind, friction, shaving, soap, surfactants, hard water having a high limestone concentration, temperature variations and sweat; said method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

55. (Twice Amended) A cosmetic [of] or dermatological method for treating sensitive, but not allergic, skin of an individual in need of such treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by exhibiting at least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema, in reaction to at least one factor selected from the group consisting of food, wind, friction, shaving, soap, surfactants, hard water having a high limestone concentration, temperature variations and sweat; said method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

85. (Twice Amended) A cosmetic or [dermatological] dermatological method for treating capsaicin-sensitive skin of an individual in need of such treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by exhibiting at

least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema, in reaction to at least one factor selected from the group consisting of food, wind, friction, shaving, soap, surfactants, hard water having a high limestone concentration, temperature variations and sweat; said method comprising topically applying to said capsaicin-sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Olivier DE LACHARRIERE et al.)	Group Art Unit: 1615
)	
Application No.: 09/735,638)	Examiner: G. Kishore
)	
Filed: December 14, 2000)	
)	
For: USE OF A SUBSTANCE P)	
ANTAGONIST IN A COSMETIC)	
COMPOSITION, AND THE)	
COMPOSITION THUS OBTAINED)	
)	

SUMMARY OF PROPOSAL I FOR INTERVIEW

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Amend the independent claims, Claims 25, 55 and 85, as set forth below.

Cancel Claims 27, 57 and 87.

This will leave Claims 25, 26, 28-51, 53-56, 58-81, 83-86, 88-111 and 113-114 in the application. (Claims 52, 82 and 112 were cancelled in the amendment dated November 5, 2001.)

25. (Twice Amended) A cosmetic or dermatological method for treating sensitive skin of an individual in need of such said treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by exhibiting at least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema; said method

comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

55. (Twice amended) A cosmetic [of] or dermatological method for treating sensitive, but not allergic, skin of an individual in need of such treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by at least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema; said method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

85. (Twice Amended) A cosmetic or [dermatological] dermatological method for treating capsaicin-sensitive skin of an individual in need of such treatment, [such] said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, [the] said sensitive skin being characterized by at least one symptom selected from the group consisting of tingling, prickling, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema; said method comprising topically applying to said capsaicin-sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said at least one substance

P antagonist is formulated into a topically applicable cosmetically- or dermatologically- acceptable medium therefor.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Olivier DE LACHARRIERE et al.)	Group Art Unit: 1615
)	
Application No.: 09/735,638)	Examiner: G. Kishore
)	
Filed: December 14, 2000)	
)	
For: USE OF A SUBSTANCE P)	
ANTAGONIST IN A COSMETIC)	
COMPOSITION, AND THE)	
COMPOSITION THUS OBTAINED)	

PENDING CLAIMS

25. A cosmetic or dermatological method for treating sensitive skin of an individual in need of such treatment, such sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, the method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

26. The method of Claim 25, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein

said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

27. The method of Claim 25, wherein the method of treatment or prevention of sensitive skin alleviates or prevents at least one neurogenic manifestation selected from the group consisting of skin irritation, desquamation, erythema, side effects of dysesthesia, side effects of overheating, and skin pruritus.

28. The method of Claim 25, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

29. The method of Claim 25, wherein said substance P antagonist is a peptide.

30. The method of Claim 25, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

31. The method of Claim 25, wherein said substance P antagonist is selected from the group consisting of 2-tricyclyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

32. The method of Claim 25, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

33. The method of Claim 32, wherein the substance P antagonist is contained in an amount ranging from between 0.0001 to 0.1 percent by weight of the total weight of the composition.

34. The method of Claim 25, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

35. The method of Claim 25, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatorys, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

36. The method of Claim 25, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

37. The method of Claim 25, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

38. The method of Claim 37, wherein said hair care composition is selected from the group consisting of a shampoo, setting lotion, hair treatment lotion, hair cream or gel, hair colorant, restructuring lotion, permanent wave composition, and an anti-hair loss lotion or gel.

39. The method of Claim 37, wherein said mouth care composition is a toothpaste.

40. The method of Claim 25, wherein said substance P antagonist is contained in an emulsion.

41. The method of Claim 37, wherein said mouth care composition contains an ingredient selected from the group consisting of a surfactant, thickener, wetting agent, polishing agent, fluoride, and a sweetener.

42. The method of Claim 40, wherein the emulsion contains a fatty phase, which comprises 5% to 80% by weight of the substance P antagonist-containing emulsion.

43. The method of Claim 40, wherein the emulsion contains an oil, an emulsifier, and a co-emulsifier.

44. The method of Claim 43, wherein the amount of emulsifier and co-emulsifier ranges from 0.3 to 30% by weight.

45. The method of Claim 25, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

46. The method of Claim 25, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

47. The method of Claim 25, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

48. The method of Claim 26, wherein said substance P antagonist is administered together with at least one agent selected from the group consisting of a skin differentiating modulating agent, a skin proliferation modulating agent, a skin pigmentation modulating agent, vitamin D, an estrogen, an antibacterial agent, an antiparasitic agent, an antifungal agent, an anti-inflammatory agent, an anesthetic agent, an anti-pruriginous agent, an antiviral agent, a keratolytic agent, an anti-free radical agent, an anti-seborrhea agent, an anti-dandruff agent, and an anti-acne agent.

49. The method of Claim 25, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

50. The method of Claim 49, wherein said active ingredient is selected from the group consisting of an α -hydroxy acid, β -hydroxy acid, α -ketonic acid, β -ketonic acid, retinoid, anthraline, anthranoid, peroxide, minoxidil, lithium salt, antimetabolite, and vitamin D compound.

51. The method of Claim 25, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

53. The method of Claim 25, wherein said sensitive skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

54. The method of Claim 53, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.

55. A cosmetic or dermatological method for treating sensitive, but not allergic, skin of an individual in need of such treatment, such sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, the method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

56. The method of Claim 55, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein

said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

57. The method of Claim 55, wherein the method of treatment or prevention of sensitive, but not allergic, skin alleviates or prevents at least one neurogenic manifestation selected from the group consisting of skin irritation, desquamation, erythema, side effects of dysesthesia, side effects of overheating, and skin pruritus.

58. The method of Claim 55, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

59. The method of Claim 55, wherein said substance P antagonist is a peptide.

60. The method of Claim 55, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

61. The method of Claim 55, wherein said substance P antagonist is selected from the group consisting of 2-tricyclyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

62. The method of Claim 55, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

63. The method of Claim 62, wherein the substance P antagonist is contained in an amount ranging from between 0.0001 to 0.1 percent by weight of the total weight of the composition.

64. The method of Claim 55, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

65. The method of Claim 55, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatorys, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

66. The method of Claim 55, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

67. The method of Claim 55, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

68. The method of Claim 67, wherein said hair care composition is selected from the group consisting of a shampoo, setting lotion, hair treatment lotion, hair cream or gel, hair colorant, restructuring lotion, permanent wave composition, and an anti-hair loss lotion or gel.

69. The method of Claim 67, wherein said mouth care composition is a toothpaste.

70. The method of Claim 55, wherein said substance P antagonist is contained in an emulsion.

71. The method of Claim 67, wherein said mouth care composition contains an ingredient selected from the group consisting of a surfactant, thickener, wetting agent, polishing agent, fluoride, and a sweetener.

72. The method of Claim 70, wherein the emulsion contains a fatty phase, which comprises 5% to 80% by weight of the substance P antagonist-containing emulsion.

73. The method of Claim 70, wherein the emulsion contains an oil, an emulsifier, and a co-emulsifier.

74. The method of Claim 73, wherein the amount of emulsifier and co-emulsifier ranges from 0.3 to 30% by weight.

75. The method of Claim 55, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

76. The method of Claim 55, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

77. The method of Claim 55, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

78. The method of Claim 56, wherein said substance P antagonist is administered together with at least one agent selected from the group consisting of an agent that affects at least one of skin differentiation, proliferation and pigmentation, vitamin D, an estrogen, antibacterial agent, antiparasitic agent, antifungal agent, anti-inflammatory agent, anesthetic agent, anti-pruriginous agent, antiviral agent, keratolytic agent, anti-free radical agent, anti-seborrhea agent, anti-dandruff agent, and anti-acne agent.

79. The method of Claim 55, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

80. The method of Claim 79, wherein said active ingredient is selected from the group consisting of an α -hydroxy acid, β -hydroxy acid, α -ketonic acid, β -ketonic acid, retinoid, anthraline, anthranoid, peroxide, minoxidil, lithium salt, antimetabolite, and vitamin D compound.

81. The method of Claim 55, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

83. The method of Claim 55, wherein said sensitive, but not allergic, skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

84. The method of Claim 83, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.

85. A cosmetic or dermatological method for treating capsaicin-sensitive skin of an individual in need of such treatment, such sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, the method comprising topically applying to said capsaicin-sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

86. The method of Claim 85, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein

said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

87. The method of Claim 85, wherein the method of treatment or prevention of capsaicin-sensitive skin alleviates or prevents at least one neurogenic manifestation selected from the group consisting of skin irritation, desquamation, erythema, side effects of dysesthesia, side effects of overheating, and skin pruritus.

88. The method of Claim 85, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

89. The method of Claim 85, wherein said substance P antagonist is a peptide.

90. The method of Claim 85, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

91. The method of Claim 85, wherein said substance P antagonist is selected from the group consisting of 2-tricyclyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

92. The method of Claim 85, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

93. The method of Claim 92, wherein the substance P antagonist is contained in an amount ranging from between 0.0001 to 0.1 percent by weight of the total weight of the composition.

94. The method of Claim 85, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

95. The method of Claim 85, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatorys, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

96. The method of Claim 85, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

97. The method of Claim 85, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

98. The method of Claim 97, wherein said hair care composition is selected from the group consisting of a shampoo, setting lotion, hair treatment lotion, hair cream or gel, hair colorant, restructuring lotion, permanent wave composition, and an anti-hair loss lotion or gel.

99. The method of Claim 97, wherein said mouth care composition is a toothpaste.

100. The method of Claim 85, wherein said substance P antagonist is contained in an emulsion.

101. The method of Claim 97, wherein said mouth care composition contains an ingredient selected from the group consisting of a surfactant, thickener, wetting agent, polishing agent, fluoride, and a sweetener.

102. The method of Claim 100, wherein the emulsion contains a fatty phase, which comprises 5% to 80% by weight of the substance P antagonist-containing emulsion.

103. The method of Claim 100, wherein the emulsion contains an oil, an emulsifier, and a co-emulsifier.

104. The method of Claim 103, wherein the amount of emulsifier and co-emulsifier ranges from 0.3 to 30% by weight.

105. The method of Claim 85, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

106. The method of Claim 85, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

107. The method of Claim 85, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

108. The method of Claim 86, wherein said substance P antagonist is administered together with at least one agent selected from the group consisting of an agent that affects at least one of skin differentiation, proliferation and pigmentation, vitamin D, an estrogen, antibacterial agent, antiparasitic agent, antifungal agent, anti-inflammatory agent, anesthetic agent, anti-pruriginous agent, antiviral agent, keratolytic agent, anti-free radical agent, anti-seborrhea agent, anti-dandruff agent, and anti-acne agent.

109. The method of Claim 85, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

110. The method of Claim 109, wherein said active ingredient is selected from the group consisting of an α -hydroxy acid, β -hydroxy acid, α -ketonic acid, β -ketonic acid, retinoid, anthraline, anthranoid, peroxide, minoxidil, lithium salt, antimetabolite, and vitamin D compound.

111. The method of Claim 85, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

113. The method of Claim 85, wherein capsaicin-sensitive skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

114. The method of Claim 85, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.